August 25, 2016
The high cost of prescription drugs in the United States is the result of drug manufacturers being granted government-protected monopolies, according to data published in JAMA Internal Medicine.
“The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers and policy makers,” Aaron S. Kesselheim, MD, JD, MPH, of the department of medicine at Brigham and Women’s Hospital and Harvard Medical School, and colleagues wrote. “In addition to their contribution to health care spending, increasing drug costs have important clinical implications. It is therefore important to understand what factors have contributed to recent medication price increases to lay the foundation for considering options to ensure that prescription drug expenditures are commensurate with their value, affordable within health budgets, and equitable for all parties involved in these complex transactions.”